stoxline Quote Chart Rank Option Currency Glossary
  
Inventiva S.A. (IVA)
2.4201  -0.08 (-3.2%)    02-06 11:21
Open: 2.51
High: 2.51
Volume: 418
  
Pre. Close: 2.5
Low: 2.4201
Market Cap: 231(M)
Technical analysis
2025-02-06 11:20:20 AM
Short term     
Mid term     
Targets 6-month :  3.11 1-year :  3.64
Resists First :  2.67 Second :  3.11
Pivot price 2.34
Supports First :  2.32 Second :  2.11
MAs MA(5) :  2.49 MA(20) :  2.3
MA(100) :  2.37 MA(250) :  2.82
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  69.8 D(3) :  68.9
RSI RSI(14): 59.2
52-week High :  4.5 Low :  1.52
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ IVA ] has closed below upper band by 21.6%. Bollinger Bands are 11.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.59 - 2.6 2.6 - 2.61
Low: 2.43 - 2.44 2.44 - 2.46
Close: 2.51 - 2.53 2.53 - 2.55
Company Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Headline News

Fri, 24 Jan 2025
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux - Yahoo Finance

Thu, 23 Jan 2025
Even after rising 18% this past week, Inventiva (EPA:IVA) shareholders are still down 77% over the past three years - Simply Wall St

Thu, 21 Nov 2024
Inventiva reports 2024 Third Quarter Financial Information¹ - GlobeNewswire

Mon, 14 Oct 2024
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday? - Benzinga

Mon, 14 Oct 2024
Stifel reiterates Buy rating on Inventiva stock, cites financing deal - Investing.com

Mon, 14 Oct 2024
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 52 (M)
Held by Insiders 1.095e+007 (%)
Held by Institutions 0 (%)
Shares Short 342 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -9.836e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 911 %
Return on Equity (ttm) -113.4 %
Qtrly Rev. Growth 1.927e+007 %
Gross Profit (p.s.) -72.47
Sales Per Share 0
EBITDA (p.s.) 2.24568e+007
Qtrly Earnings Growth -2.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -85 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -1.35
Stock Dividends
Dividend 0
Forward Dividend 344870
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android